Meeting
2019 Genitourinary Cancers Symposium
Genomic determinants of sensitivity to bipolar androgen therapy (BAT) in castrate-resistant prostate cancer (CRPC).
Authors
Michael Thomas Schweizer
University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
Michael Thomas Schweizer , Emmanuel S. Antonarakis , Mario A. Eisenberger , Peter Nelson , Jun Luo , Colin Pritchard , Samuel R. Denmeade
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 200)
DOI
10.1200/JCO.2019.37.7_suppl.200
Abstract #
200
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Survival impact of homologous recombination deficiency in veterans with cholangiocarcinoma including mutual exclusivity with pathogenic KRAS and TP53.
First Author: Colin P. Bergstrom
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2023 ASCO Genitourinary Cancers Symposium
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh